Pathogenesis of Atopic Dermatitis: Current Paradigm

研究成果: ジャーナルへの寄稿評論記事

2 引用 (Scopus)

抄録

Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. In this review, recent advances in the pathogenesis of AD are summarized. Clinical efficacy of the anti-IL-4 receptor antibody dupilumab implies that type 2 cytokines IL-4 and IL-13 have pivotal roles in atopic inflammation. The expression of IL-4 and IL-13 as well as type 2 chemokines such as CCL17, CCL22 and CCL26 is increased in the lesional skin of AD. In addition, IL-4 and IL-13 down-regulate the expression of filaggrin in keratinocytes and exacerbate epidermal barrier dysfunction. Keratinocytes in barrier-disrupted epidermis produce large amounts of thymic stromal lymphopoietin, IL-25 and IL-33, conducing to type 2 immune deviation via OX40L/OX40 signaling. IL-31, produced by type 2 T cells, is a cardinal pruritogenic cytokine. IL-4 and IL-13 also amplify the IL-31-mediated sensory nerve signal. These molecules are particularly important targets for future drug development for AD.

元の言語英語
ページ(範囲)97-107
ページ数11
ジャーナルIranian journal of immunology : IJI
16
発行部数2
DOI
出版物ステータス出版済み - 6 1 2019

Fingerprint

Interleukin-13
Atopic Dermatitis
Interleukin-4
Keratinocytes
Interleukin-4 Receptors
Cytokines
Inflammation
Skin
Pruritus
Chemokines
Epidermis
Down-Regulation
T-Lymphocytes
Antibodies
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

これを引用

Pathogenesis of Atopic Dermatitis : Current Paradigm. / Furue, Masutaka; Ulzii, Dugarmaa; Vu, Yen Hai; Tsuji, Gaku; Kido-Nakahara, Makiko; Nakahara, Takeshi.

:: Iranian journal of immunology : IJI, 巻 16, 番号 2, 01.06.2019, p. 97-107.

研究成果: ジャーナルへの寄稿評論記事

@article{bbbcbf22e1574dc3ba146d80e7656713,
title = "Pathogenesis of Atopic Dermatitis: Current Paradigm",
abstract = "Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. In this review, recent advances in the pathogenesis of AD are summarized. Clinical efficacy of the anti-IL-4 receptor antibody dupilumab implies that type 2 cytokines IL-4 and IL-13 have pivotal roles in atopic inflammation. The expression of IL-4 and IL-13 as well as type 2 chemokines such as CCL17, CCL22 and CCL26 is increased in the lesional skin of AD. In addition, IL-4 and IL-13 down-regulate the expression of filaggrin in keratinocytes and exacerbate epidermal barrier dysfunction. Keratinocytes in barrier-disrupted epidermis produce large amounts of thymic stromal lymphopoietin, IL-25 and IL-33, conducing to type 2 immune deviation via OX40L/OX40 signaling. IL-31, produced by type 2 T cells, is a cardinal pruritogenic cytokine. IL-4 and IL-13 also amplify the IL-31-mediated sensory nerve signal. These molecules are particularly important targets for future drug development for AD.",
author = "Masutaka Furue and Dugarmaa Ulzii and Vu, {Yen Hai} and Gaku Tsuji and Makiko Kido-Nakahara and Takeshi Nakahara",
year = "2019",
month = "6",
day = "1",
doi = "10.22034/IJI.2019.80253",
language = "English",
volume = "16",
pages = "97--107",
journal = "Iranian Journal of Immunology",
issn = "1735-1383",
publisher = "Shiraz University of Medical Sciences",
number = "2",

}

TY - JOUR

T1 - Pathogenesis of Atopic Dermatitis

T2 - Current Paradigm

AU - Furue, Masutaka

AU - Ulzii, Dugarmaa

AU - Vu, Yen Hai

AU - Tsuji, Gaku

AU - Kido-Nakahara, Makiko

AU - Nakahara, Takeshi

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. In this review, recent advances in the pathogenesis of AD are summarized. Clinical efficacy of the anti-IL-4 receptor antibody dupilumab implies that type 2 cytokines IL-4 and IL-13 have pivotal roles in atopic inflammation. The expression of IL-4 and IL-13 as well as type 2 chemokines such as CCL17, CCL22 and CCL26 is increased in the lesional skin of AD. In addition, IL-4 and IL-13 down-regulate the expression of filaggrin in keratinocytes and exacerbate epidermal barrier dysfunction. Keratinocytes in barrier-disrupted epidermis produce large amounts of thymic stromal lymphopoietin, IL-25 and IL-33, conducing to type 2 immune deviation via OX40L/OX40 signaling. IL-31, produced by type 2 T cells, is a cardinal pruritogenic cytokine. IL-4 and IL-13 also amplify the IL-31-mediated sensory nerve signal. These molecules are particularly important targets for future drug development for AD.

AB - Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. In this review, recent advances in the pathogenesis of AD are summarized. Clinical efficacy of the anti-IL-4 receptor antibody dupilumab implies that type 2 cytokines IL-4 and IL-13 have pivotal roles in atopic inflammation. The expression of IL-4 and IL-13 as well as type 2 chemokines such as CCL17, CCL22 and CCL26 is increased in the lesional skin of AD. In addition, IL-4 and IL-13 down-regulate the expression of filaggrin in keratinocytes and exacerbate epidermal barrier dysfunction. Keratinocytes in barrier-disrupted epidermis produce large amounts of thymic stromal lymphopoietin, IL-25 and IL-33, conducing to type 2 immune deviation via OX40L/OX40 signaling. IL-31, produced by type 2 T cells, is a cardinal pruritogenic cytokine. IL-4 and IL-13 also amplify the IL-31-mediated sensory nerve signal. These molecules are particularly important targets for future drug development for AD.

UR - http://www.scopus.com/inward/record.url?scp=85067815466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067815466&partnerID=8YFLogxK

U2 - 10.22034/IJI.2019.80253

DO - 10.22034/IJI.2019.80253

M3 - Review article

C2 - 31182684

AN - SCOPUS:85067815466

VL - 16

SP - 97

EP - 107

JO - Iranian Journal of Immunology

JF - Iranian Journal of Immunology

SN - 1735-1383

IS - 2

ER -